Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715134 | 0.82 | HRH3 (0.32) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL14378317 | 0.77 | HRH3 (0.33) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL21473019 | 0.73 | HRH3 (0.32) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL12890613 | 0.71 | HRH3 (0.39) | HRH3CYP2D6KCNH2CHRNA7ALDH1A1 | |
| SCHEMBL23103447 | 0.70 | CHRNA7 (0.37) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL12026409 | 0.70 | CHRNA7 (0.37) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL23384462 | 0.70 | CHRNA7 (0.37) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL23103444 | 0.70 | CHRNA7 (0.37) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL20711781 | 0.70 | — | — | |
| SCHEMBL22566191 | 0.70 | HRH3 (0.36) | HRH3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HRH3 3415/4885CYP2D6 1629/4885KCNH2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.